Melanoma

Oncologist

Volumn 6, Issue 5, 2001, Pages 402-406

  Gershenwald, Jeffrey E ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biochemotherapy; Chemoprevention; Interferon; Melanoma; Metastasis; Sentinel node biopsy; Vaccine

Indexed keywords

CANCER VACCINE; CYTOKINE; HEAT SHOCK PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; MELACINE; MEVINOLIN; TEMOZOLOMIDE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; HUMAN; MELANOMA; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; UNITED KINGDOM; VACCINATION;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CHEMOPREVENTION; CHEMOTHERAPY, ADJUVANT; HUMANS; INTERFERONS; LOVASTATIN; MELANOMA; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; SENTINEL LYMPH NODE BIOPSY;

EID: 0034750310     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-5-402     Document Type: Conference Paper

References (14)

1. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
2. Prognostic factor analysis of 17,600 melanoma patients: Validation of the new American Joint Committee on Cancer melanoma staging system
3. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
4. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma
5. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence
6. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon interleukin-2 for patients with metastatic melanoma
7. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma
8. Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL-2) and interferon-alpha-2b (INF) Versus CVD in patients (pts) with metastatic melanoma
9. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
10. Risk reduction endpoints should be part of the design of adjuvant therapy clinical trials for patients with melanoma. A commentary
11. Re: Greying of America will foster new strategies in oncology
12. Association of HLA phenotype with response to active specific immunotherapy of melanoma
13. Adjuvant therapy of T3NOMO melanoma with an allogeneic tumor vaccine: Results of SWOG trial 9035
14. +) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide